BW-40202 / Argo Biopharma - LARVOL DELTA

A Phase 1 Clinical Study in Healthy Participants (clinicaltrials.gov) - P1 | N=40 | Not yet recruiting | Sponsor: Shanghai Argo Biopharmaceutical Co., Ltd.

New P1 trial

Argo Biopharmaceutical…announced the first patient has been dosed in multiple Phase II studies of BW-40202, an investigational siRNA therapy targeting complement factor B (CFB) (PRNewswire) - "Each Phase II clinical trial has been designed to evaluate BW-40202 as a potential treatment for patients suffering from complement-mediated diseases paroxysmal nocturnal hemoglobinuria (PNH) and immunoglobulin A nephropathy (IgAN)."

Trial status • IgA Nephropathy • Paroxysmal Nocturnal Hemoglobinuria

Argo Biopharma Receives IND Approval from NMPA for Phase II Clinical Trial of siRNA Therapy, BW-40202, for the Treatment of PNH (PRNewswire) - "The study is expected to commence in January 2026."

New P2 trial • Paroxysmal Nocturnal Hemoglobinuria